Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748219 | 0.86 | F2RL1 (0.43) | MAPTRECQLPRKDCKCNH2BRD4 | |
| SCHEMBL23748146 | 0.85 | SQOR (0.30) | SQORTSHR | |
| SCHEMBL23748161 | 0.83 | MAPT (0.43) | MAPTRECQLKCNH2BRD4KDM4E | |
| SCHEMBL23748230 | 0.79 | MAPT (0.39) | MAPTRECQLPRKDCKCNH2KDM4E | |
| SCHEMBL23748295 | 0.74 | F2RL1 (0.33) | SQOR | |
| SCHEMBL23748188 | 0.72 | MAPT (0.41) | MAPTKDM4ESQORTSHR | |
| SCHEMBL23748168 | 0.72 | MAPT (0.44) | MAPTRECQLKCNH2KDM4ETSHR | |
| SCHEMBL23748213 | 0.69 | LIG1 (0.43) | MAPTKDM4ETSHR | |
| SCHEMBL23748227 | 0.69 | SLC6A2 (0.33) | MAPTKCNH2TSHR | |
| SCHEMBL23748201 | 0.69 | CTSA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | JANSSEN BIOPHARMA INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | Janssen Biopharma, Inc. (US) | 2022-04-26 | — | — | US | disclosed |
| EP-3864020-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | Janssen BioPharma, Inc. (US) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002409-A1 | MACROCYCLIC FLU ENDONUCLEASE INHIBITORS | ACE, PNP, FEN1 | MAPT 2999/4885RECQL 243/4885PRKDC 477/4885 |
| US-11312727-B1 | Macrocyclic flu endonuclease inhibitors | ACE, FEN1, PNP | MAPT 3026/4885RECQL 134/4885PRKDC 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.